News

Théa and Coave Therapeutics announce their partnership

Théa and Nevakar sign an exclusive licensing agreement

Théa and Nevakar sign an exclusive licensing agreement for a unique therapeutic solution in the treatment of myopia progression in children.

Signing of an exclusive Licensing Agreement with Ripple Therapeutics Corp.

Théa Open Innovation signs an exclusive Licensing Agreement for the rights on Ripple Therapeutics Corporation lead product, IBE-814 for North America and Europe.

Théa and EVEON announce their partnership

EVEON, designer and maker of medical devices for the preparation and administration of drugs, and Théa, European leader in the field of ophthalmology, announce their partnership in the development of innovative medical technologies.

Consolidation of the collaboration with OliX

OliX Pharmaceuticals Announces Expansion of Collaboration with Laboratoires Théa to Develop siRNA Therapeutics for Ophthalmic Diseases.

Théa and Biocorp sign a partnership

BIOCORP, a French company specialized in the development and manufacturing of medical devices and smart drug delivery systems, announces the signature of a partnership agreement with Théa.

Théa & ELSALYS BIOTECH conclude a license option agreement

The option concerns the clinical development (expected from 2020) and the commercialization of ELB011, a new first-in-class antibody in the treatment of wet AMD and other retinal vascular pathologies.

Théa Open Innovation and Olix sign a partnership

Théa Open Innovation has just signed a license and collaboration agreement for the OLX301A programme, an innovative new treatment for wet and dry age-related macular degeneration, with OliX Pharmaceuticals, a clinical stage pharmaceutical company which develops treatments for retinal vascular diseases in particular.

Contact us